Related Content
- Lannett ships morphine product
- Lannett receives FDA approval for generic Ionamin
- New alliance will crack down on adulterated products touting dietary supplement claims
- Sandoz announces FDA approval, U.S. launch of chemotherapy drug
- FDA, parent agency HHS divided over emergency contraceptive prescription status
BEDMINSTER, N.J. — The Food and Drug Administration will decide in late August whether to approve an experimental opioid painkiller made by QRxPharma, the drug maker said Thursday.
Australia-based QRxPharma is seeking approval for Moxduo (morphine and oxycodone), and the FDA plans to decide whether to approve the drug on Aug. 26.
"We are pleased that the FDA has formally accepted our resubmitted Moxduo [new drug application]," QRxPharma CEO and managing director John Holaday said. "We expect the advisory committee meeting to be scheduled between late June and late July and will update shareholders once formal notification has been received."
